All In Biotech

Drug Trial Radar · NCT06126783

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

91

Actual

Start

Oct 20, 2023

Primary completion

Sep 23, 2025

Study completion Sep 23, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease

Conditions

  • Thyroid Eye Disease, TED

Interventions

  • IBI311Drug

    The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The response rate of exophthalmos was studied.Time frame: After receiving IBI311 treatment for 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.